Needham analyst David Saxon raised the firm’s price target on iRhythm (IRTC) to $125 from $112 and keeps a Buy rating on the shares as part of a broader research note on MedTech/Diagnostics sector. Following the recent pre-announcements and management commentary, the firm is updating its forecasts on select names while also rolling forward its valuation framework to 2026 estimates, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRTC:
- iRhythm Technologies Reports Strong Growth and Innovation
- iRhythm sees FY24 revenue slightly above high end of previous guidance range
- iRhythm price target raised to $120 from $105 at Oppenheimer
- iRhythm price target raised to $111 from $85 at Truist
- iRhythm price target raised to $152 from $125 at Canaccord